Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tanespimycin - Kosan Biosciences

X
Drug Profile

Tanespimycin - Kosan Biosciences

Alternative Names: 17-AAG; 17-allylamino-17-demethoxy-geldanamycin; KOS-953

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA)
  • Developer Kosan Biosciences
  • Class Antineoplastics; Benzoquinones; Cytostatic antibiotics; Macrocyclic lactams; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HER2 positive breast cancer; Malignant melanoma; Multiple myeloma

Most Recent Events

  • 05 Dec 2009 Efficacy, adverse events and pharmacodynamics data from a phase II/III trial in Multiple myeloma presented at the 51st Annual Meeting and Exposition of the American Society of Hematology (ASH-2009)
  • 04 Dec 2009 No development reported - Phase-II for Malignant melanoma in Australia (IV)
  • 04 Dec 2009 No development reported - Phase-II for Malignant melanoma in USA (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top